Rapport Therapeutics (RAPP) Times Interest Earned (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Times Interest Earned of -$0.2 for Q1 2026, down 8689.82% year-over-year from $0.0 in Q1 2025, and up 42.19% quarter-over-quarter from -$0.34 in Q4 2025.
Rapport Therapeutics (RAPP) Times Interest Earned (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Times Interest Earned for 4 consecutive years, with -$0.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 8689.82% year-over-year to -$0.2; the TTM figure through Mar 2026 stood at -$0.99 (down 12820.53% YoY), while the FY2025 annual figure was -$1.1, up 54.59% from the prior year.
- Times Interest Earned grew to -$0.2 in Q1 2026 per RAPP's latest filing, from -$0.34 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.0 in Q1 2025 and bottomed at -$1.76 in Q2 2025.
- Historically, Times Interest Earned has averaged -$0.59 across 4 years, with a median of -$0.43 in 2024.
- Annual changes were most pronounced in 2025 — Times Interest Earned surged 50.64% — and 2026, when it sank 8689.82%.
- Rapport Therapeutics' Times Interest Earned stood at -$1.13 in 2023, then soared by 39.11% to -$0.69 in 2024, then soared by 50.64% to -$0.34 in 2025, then soared by 42.19% to -$0.2 in 2026.
- Business Quant data shows RAPP's Times Interest Earned at -$0.2 in Q1 2026, -$0.34 in Q4 2025, and -$0.27 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -0.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.30 |
| Mar 31, 2026 | -0.20 |
| Dec 31, 2025 | -0.34 |
| Sep 30, 2025 | -0.27 |
| Jun 30, 2025 | -1.76 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | -0.69 |
| Sep 30, 2024 | -0.48 |
| Jun 30, 2024 | -0.37 |
| Dec 31, 2023 | -1.13 |
| Jun 30, 2023 | -0.69 |